APO RESEARCH · REPORT
Hydroxycarbamide
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Product & engineering
Understand the product.
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Selected research
Market Structure
Global Hydroxycarbamide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Global Hydroxycarbamide key players include Qilu Pharmaceutical, Beijing Jialin Pharma, Taj Pharma, etc. Global top three manufacturers hold a share over 35%.
Read the full market overview
Asia-Pacific is the largest market, with a share nearly 60%, followed by Europe, and North America, both have a share about 40 percent.
In terms of product, Capsule is the largest segment, with a share over 60%. And in terms of application, the largest application is Sickle Cell Disease, followed by Cancer, etc.
This report provides an overview of the global Hydroxycarbamide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Hydroxycarbamide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Hydroxycarbamide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hydroxycarbamide market size, projected growth trends, production technologies, key applications, and end-use industries.
Hydroxycarbamide Segment by Company
Bristol Myers Squibb
Taj Pharma
Beijing Jialin Pharma
Qilu Pharmaceutical
Teva Pharma
Cipla
Zydus Cadila
United Biotech
Par Pharma
Khandelwal Laboratories
Alkem (Cytomed)
Samarth Pharma
VHB Life Sciences
Hydroxycarbamide Segment by Type
Capsule
Tablet
Hydroxycarbamide Segment by Application
Sickle Cell Disease
Cancer
Others
Hydroxycarbamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hydroxycarbamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hydroxycarbamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hydroxycarbamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Hydroxycarbamide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hydroxycarbamide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hydroxycarbamide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hydroxycarbamide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Tablet
Applications
- Sickle Cell Disease
- Cancer
- Others
Companies covered
- Bristol Myers Squibb
- Taj Pharma
- Beijing Jialin Pharma
- Qilu Pharmaceutical
- Teva Pharma
- Cipla
- Zydus Cadila
- United Biotech
- Par Pharma
- Khandelwal Laboratories
- Alkem (Cytomed)
- Samarth Pharma
- VHB Life Sciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Hydroxycarbamide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Hydroxycarbamide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Hydroxycarbamide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Hydroxycarbamide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Hydroxycarbamide Market Dynamics
- 2.1 Hydroxycarbamide Industry Trends
- 2.2 Hydroxycarbamide Industry Drivers
- 2.3 Hydroxycarbamide Industry Opportunities and Challenges
- 2.4 Hydroxycarbamide Industry Restraints
3 Hydroxycarbamide Market by Manufacturers
- 3.1 Global Hydroxycarbamide Revenue by Manufacturers (2021-2026)
- 3.2 Global Hydroxycarbamide Sales by Manufacturers (2021-2026)
- 3.3 Global Hydroxycarbamide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Hydroxycarbamide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Hydroxycarbamide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Hydroxycarbamide Manufacturers, Product Type & Application
- 3.7 Global Hydroxycarbamide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Hydroxycarbamide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Hydroxycarbamide Players Market Share by Revenue in 2025
- 3.8.3 2025 Hydroxycarbamide Tier 1, Tier 2, and Tier 3
4 Hydroxycarbamide Market by Type
- 4.1 Hydroxycarbamide Type Introduction
- 4.1.1 Capsule
- 4.1.2 Tablet
- 4.2 Global Hydroxycarbamide Sales by Type
- 4.2.1 Global Hydroxycarbamide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Hydroxycarbamide Sales by Type (2021-2032)
- 4.2.3 Global Hydroxycarbamide Sales Market Share by Type (2021-2032)
- 4.3 Global Hydroxycarbamide Revenue by Type
- 4.3.1 Global Hydroxycarbamide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Hydroxycarbamide Revenue by Type (2021-2032)
- 4.3.3 Global Hydroxycarbamide Revenue Market Share by Type (2021-2032)
5 Hydroxycarbamide Market by Application
- 5.1 Hydroxycarbamide Application Introduction
- 5.1.1 Sickle Cell Disease
- 5.1.2 Cancer
- 5.1.3 Others
- 5.2 Global Hydroxycarbamide Sales by Application
- 5.2.1 Global Hydroxycarbamide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Hydroxycarbamide Sales by Application (2021-2032)
- 5.2.3 Global Hydroxycarbamide Sales Market Share by Application (2021-2032)
- 5.3 Global Hydroxycarbamide Revenue by Application
- 5.3.1 Global Hydroxycarbamide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Hydroxycarbamide Revenue by Application (2021-2032)
- 5.3.3 Global Hydroxycarbamide Revenue Market Share by Application (2021-2032)
6 Global Hydroxycarbamide Sales by Region
- 6.1 Global Hydroxycarbamide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Hydroxycarbamide Sales by Region (2021-2032)
- 6.2.1 Global Hydroxycarbamide Sales by Region (2021-2026)
- 6.2.2 Global Hydroxycarbamide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Hydroxycarbamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Hydroxycarbamide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Hydroxycarbamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Hydroxycarbamide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Hydroxycarbamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Hydroxycarbamide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Hydroxycarbamide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Hydroxycarbamide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Hydroxycarbamide Revenue by Region
- 7.1 Global Hydroxycarbamide Revenue by Region
- 7.1.1 Global Hydroxycarbamide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Hydroxycarbamide Revenue by Region (2021-2026)
- 7.1.3 Global Hydroxycarbamide Revenue by Region (2027-2032)
- 7.1.4 Global Hydroxycarbamide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Hydroxycarbamide Revenue (2021-2032)
- 7.2.2 North America Hydroxycarbamide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Hydroxycarbamide Revenue (2021-2032)
- 7.3.2 Europe Hydroxycarbamide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Hydroxycarbamide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Hydroxycarbamide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Hydroxycarbamide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Hydroxycarbamide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bristol Myers Squibb
- 8.1.1 Bristol Myers Squibb Company Information
- 8.1.2 Bristol Myers Squibb Business Overview
- 8.1.3 Bristol Myers Squibb Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bristol Myers Squibb Hydroxycarbamide Product Portfolio
- 8.1.5 Bristol Myers Squibb Recent Developments
- 8.2 Taj Pharma
- 8.2.1 Taj Pharma Company Information
- 8.2.2 Taj Pharma Business Overview
- 8.2.3 Taj Pharma Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Taj Pharma Hydroxycarbamide Product Portfolio
- 8.2.5 Taj Pharma Recent Developments
- 8.3 Beijing Jialin Pharma
- 8.3.1 Beijing Jialin Pharma Company Information
- 8.3.2 Beijing Jialin Pharma Business Overview
- 8.3.3 Beijing Jialin Pharma Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Beijing Jialin Pharma Hydroxycarbamide Product Portfolio
- 8.3.5 Beijing Jialin Pharma Recent Developments
- 8.4 Qilu Pharmaceutical
- 8.4.1 Qilu Pharmaceutical Company Information
- 8.4.2 Qilu Pharmaceutical Business Overview
- 8.4.3 Qilu Pharmaceutical Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Qilu Pharmaceutical Hydroxycarbamide Product Portfolio
- 8.4.5 Qilu Pharmaceutical Recent Developments
- 8.5 Teva Pharma
- 8.5.1 Teva Pharma Company Information
- 8.5.2 Teva Pharma Business Overview
- 8.5.3 Teva Pharma Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Teva Pharma Hydroxycarbamide Product Portfolio
- 8.5.5 Teva Pharma Recent Developments
- 8.6 Cipla
- 8.6.1 Cipla Company Information
- 8.6.2 Cipla Business Overview
- 8.6.3 Cipla Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Cipla Hydroxycarbamide Product Portfolio
- 8.6.5 Cipla Recent Developments
- 8.7 Zydus Cadila
- 8.7.1 Zydus Cadila Company Information
- 8.7.2 Zydus Cadila Business Overview
- 8.7.3 Zydus Cadila Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Zydus Cadila Hydroxycarbamide Product Portfolio
- 8.7.5 Zydus Cadila Recent Developments
- 8.8 United Biotech
- 8.8.1 United Biotech Company Information
- 8.8.2 United Biotech Business Overview
- 8.8.3 United Biotech Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 United Biotech Hydroxycarbamide Product Portfolio
- 8.8.5 United Biotech Recent Developments
- 8.9 Par Pharma
- 8.9.1 Par Pharma Company Information
- 8.9.2 Par Pharma Business Overview
- 8.9.3 Par Pharma Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Par Pharma Hydroxycarbamide Product Portfolio
- 8.9.5 Par Pharma Recent Developments
- 8.10 Khandelwal Laboratories
- 8.10.1 Khandelwal Laboratories Company Information
- 8.10.2 Khandelwal Laboratories Business Overview
- 8.10.3 Khandelwal Laboratories Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Khandelwal Laboratories Hydroxycarbamide Product Portfolio
- 8.10.5 Khandelwal Laboratories Recent Developments
- 8.11 Alkem (Cytomed)
- 8.11.1 Alkem (Cytomed) Company Information
- 8.11.2 Alkem (Cytomed) Business Overview
- 8.11.3 Alkem (Cytomed) Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Alkem (Cytomed) Hydroxycarbamide Product Portfolio
- 8.11.5 Alkem (Cytomed) Recent Developments
- 8.12 Samarth Pharma
- 8.12.1 Samarth Pharma Company Information
- 8.12.2 Samarth Pharma Business Overview
- 8.12.3 Samarth Pharma Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Samarth Pharma Hydroxycarbamide Product Portfolio
- 8.12.5 Samarth Pharma Recent Developments
- 8.13 VHB Life Sciences
- 8.13.1 VHB Life Sciences Company Information
- 8.13.2 VHB Life Sciences Business Overview
- 8.13.3 VHB Life Sciences Hydroxycarbamide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 VHB Life Sciences Hydroxycarbamide Product Portfolio
- 8.13.5 VHB Life Sciences Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Hydroxycarbamide Value Chain Analysis
- 9.1.1 Hydroxycarbamide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Hydroxycarbamide Production Mode & Process
- 9.2 Hydroxycarbamide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Hydroxycarbamide Distributors
- 9.2.3 Hydroxycarbamide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst